homehealthcare NewsNatco Pharma's marketing partner gets USFDA nod for cancer treatment drug

Natco Pharma's marketing partner gets USFDA nod for cancer treatment drug

Natco Pharma's marketing partner gets USFDA nod for cancer treatment drug
Profile image

By PTI Nov 13, 2020 1:09:00 PM IST (Published)

Drug major Natco Pharma on Friday said its marketing partner Breckenridge Pharmaceutical has received final approval from the US health regulator for Pomalidomide Capsules, treatment of patients suffering from multiple myeloma cancer. "Breckenridge Pharmaceutical Inc. has received final approval for its abbreviated new drug application (ANDA) for Pomalidomide Capsules from the US Food and Drug Administration (USFDA)," Natco Pharma said in a regulatory filing. In addition, Natco and Breckenridge have settled the patent litigation with Celgene (now part of BristolMyers Squibb) in the US district court for this product, the company added. The company, however, did not share details of the settlement.

Drug major Natco Pharma on Friday said its marketing partner Breckenridge Pharmaceutical has received final approval from the US health regulator for Pomalidomide Capsules, treatment of patients suffering from multiple myeloma cancer. ”Breckenridge Pharmaceutical Inc. has received final approval for its abbreviated new drug application (ANDA) for Pomalidomide Capsules from the US Food and Drug Administration (USFDA),” Natco Pharma said in a regulatory filing.

Recommended Articles

View All

In addition, Natco and Breckenridge have settled the patent litigation with Celgene (now part of Bristol-Myers Squibb) in the US district court for this product, the company added. The company, however, did not share details of the settlement.
Celgene sells Pomalidomide Capsules under Brand name Pomalyst in the USA market which is indicated for the treatment of patients suffering from multiple myeloma cancer.
Natco Pharma said as per industry sales data, Pomalyst had annual sales of USD 957 million during the twelve months ending September 2020. Shares of Natco Pharma were trading 0.50 percent higher at Rs 910.40 apiece on BSE.
Check out our in-depth Market Coverage, Business News & get real-time Stock Market Updates on CNBC-TV18. Also, Watch our channels CNBC-TV18, CNBC Awaaz and CNBC Bajar Live on-the-go!

Top Budget Opinions

    Most Read

    Market Movers

    View All
    Top GainersTop Losers
    CurrencyCommodities
    CompanyPriceChng%Chng